Verzenio fda approval date?

When did Verzenio (abemaciclib) get FDA approval?

Verzenio (abemaciclib) received its first FDA approval on September 10, 2017. [1]

What was Verzenio initially approved for?

At the time of approval in 2017, Verzenio was approved for HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor for people with disease not previously treated with endocrine therapy. [1]

Are there later FDA approvals or label expansions after 2017?

Verzenio’s FDA approval history includes additional approvals and label updates after the first approval date (for other combinations and settings). Exact dates depend on the specific supplemental approval or indication. [1]

Where can I verify the approval date and related FDA history?

You can check Verzenio’s FDA timeline and related drug/IP coverage details through DrugPatentWatch.com: [1]

Sources:
[1] DrugPatentWatch.com — Verzenio (abemaciclib)